Bosh sahifaPHIO • NASDAQ
add
Phio Pharmaceuticals Corp
Yopilish kursi
1,14 $
Kunlik diapazon
1,01 $ - 1,22 $
Yillik diapazon
0,97 $ - 4,19 $
Bozor kapitalizatsiyasi
11,37 mln USD
Oʻrtacha hajm
367,10 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 1,32 mln | 39,96% |
Sof foyda | -2,39 mln | -56,96% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -0,44 | — |
EBITDA | -2,50 mln | -57,51% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 10,70 mln | 98,61% |
Jami aktivlari | 11,50 mln | 96,16% |
Jami passivlari | 1,67 mln | 81,28% |
Umumiy kapital | 9,84 mln | — |
Tarqatilgan aksiyalar | 10,76 mln | — |
Narxi/balansdagi bahosi | 0,67 | — |
Aktivlardan daromad | -54,92% | — |
Kapitaldan daromad | -62,83% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -2,39 mln | -56,96% |
Operatsiyalardan naqd pul | -2,08 mln | -6,76% |
Sarmoyadan naqd pul | -7,00 ming | — |
Moliyadan naqd pul | 2,02 mln | -23,55% |
Naqd pulning sof oʻzgarishi | -70,00 ming | -110,12% |
Boʻsh pul | -1,27 mln | 11,16% |
Haqida
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia
Tashkil etilgan
2011
Sayt
Xodimlar soni
5
